Enterprise record
Estrella Immunopharma, Inc.
Public governance Claims and source records for this enterprise.
More
Alpha ID: alpha:company:a73ed67a-45ed-4a5a-a5e9-0c2e4194c024Version: public-1As of: unavailable
6 published Claims3 sources
Key Claims
Board and committees
Evidence, history and coverage
Additional published Claims
Published evidence records
3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Alpha canonical company public projection
canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026
Supports 3 claims
- Legal Name: Estrella Immunopharma, Inc. · Claim reviewed: Sep 29, 2026
- Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
- Published Fact: US · Claim reviewed: Sep 29, 2026
Estrella Immunopharma, Inc. DEF 14A 2023-06-16
sec proxy · Source published: Jun 16, 2023 · Retrieved: Apr 29, 2026
Supports 2 claims
- Leadership Role: Jason Long: Director · Claim reviewed: Sep 29, 2026
- Leadership Role: Tao Jiang: Director · Claim reviewed: Sep 29, 2026
ESLA 10-K executive officers
sec filing · Source published: Mar 18, 2026 · Retrieved: May 16, 2026
Supports 1 claim
- Leadership Role: Not provided in excerpt: Chief Financial Officer · Claim reviewed: Sep 29, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-09-29
- Board and committees
- published
- Control and shareholders
- not observed
- Compensation
- not observed
- Auditors, advisors and reporting
- not observed
- Legal
- not observed
- AI governance
- not observed

